When Will Generic Ozempic, Wegovy, and Zepbound Launch? The GLP-1 Patent Timeline

If you are waiting for a cheap generic of Ozempic, Wegovy, Mounjaro, or Zepbound to arrive in a US pharmacy, the honest answer from the patent record is: not soon. The main US compound patent on semaglutide runs until December 5, 2031, and the main compound patent on tirzepatide runs until January 5, 2036. Layered on top of those are dozens of follow-on patents and FDA exclusivities that, in practice, push the earliest realistic generic entry for the weight-loss brands toward the early-to-mid 2030s for semaglutide and the late 2030s for tirzepatide — with compounded GLP-1s and a single newly generic older drug (liraglutide) as the only cheaper options in the meantime.

Those dates are not editorial spin. They come straight from the FDA Approved Drug Products with Therapeutic Equivalence Evaluations — the "Orange Book" — the official public register of the patents and exclusivities that protect every brand-name drug in the United States. This page reads that record directly, explains why "the patent expired" headlines about India and Brazil do not apply to the US, and lays out what the slow generic timeline means for patients who came to GLP-1 drugs through aesthetic medicine — the weight loss that precedes facial-volume loss and body-contouring work.

What the FDA Orange Book actually says about semaglutide

Semaglutide is the active ingredient in three Novo Nordisk brands: Ozempic (diabetes, approved 2017), Rybelsus (oral, approved 2019), and Wegovy (weight loss, approved 2021). Reading the Orange Book patent listings for these applications surfaces a clear, if unsatisfying, picture.

The single most important entry is the compound patent that covers the semaglutide molecule itself, US Patent 8,129,343. Left to a strict 20-year clock from its filing, that patent would have expired in March 2026 — and indeed semaglutide did lose its underlying patent protection in countries like India on exactly that schedule, triggering a flood of generics in March 2026. In the United States, however, Patent Term Adjustment and Patent Term Extension stretched that same patent to December 5, 2031. That five-year gap is the difference between "generic semaglutide is here" and "generic semaglutide is years away."

On top of the '343 compound patent, Novo Nordisk has listed a thicket of follow-on patents covering formulations, injection devices, and methods of treatment. A direct read of the Orange Book for the relevant applications shows the practical ceiling those patents create:

The pattern is the whole story: the compound patent ends in late 2031, but the latest listed patents run out to 2038–2041. Independent patent analysts have concluded from exactly this record that generic Ozempic is most likely to enter the US market around 2032, while Wegovy — which carries the thickest set of late-2030s formulation patents — may not see generic competition until closer to 2040 unless a generic challenger invalidates or designs around those later patents in court.

There has already been movement behind those dates. In October 2024 Novo Nordisk reached a confidential settlement with generic challengers (including Natco Pharma and Mylan/Viatris) over Ozempic; the undisclosed terms govern when those generics may actually launch, and they could fall anywhere between the 2031 compound-patent expiry and the later follow-on dates. The first generic company to file an FDA application (an ANDA with a Paragraph IV challenge) also earns a 180-day exclusivity window as the sole generic — a prize that is driving aggressive early filings but does not shorten the underlying patents.

What the Orange Book says about tirzepatide

Tirzepatide — Eli Lilly's dual GLP-1/GIP agonist in Mounjaro (diabetes, approved May 2022) and Zepbound (weight loss, approved November 2023; sleep apnea added December 2024) — sits a few years behind semaglutide in its patent life, which means generics are even further off.

The core compound patent covering tirzepatide is US Patent 9,474,780 (the '780 patent), which covers the molecule and a broader genus of GLP-1/GIP-targeting compounds. Per the Orange Book and confirmed by patent analysts, it expires in the US on January 5, 2036. Tirzepatide also enjoys New Chemical Entity (NCE) exclusivity until May 13, 2027 — a statutory FDA protection that runs alongside the patents and blocks an ANDA from even being accepted with a Paragraph IV challenge until the "NCE-1" date of May 13, 2026 (four years after first approval).

Again the headline is the gap between the compound patent (2036) and the trailing patents (2039–2041). Multiple analysts peg the realistic earliest US generic launch of tirzepatide at 2036 at the very earliest, and more plausibly 2039–2041 once the follow-on formulation and device patents are accounted for. Eli Lilly is also actively adding patents — the Orange Book listing grows over time — which tends to push that window later, not earlier. The practical upshot: a true generic Zepbound or Mounjaro is roughly a decade away in the United States.

Why did generic semaglutide launch in India in 2026 but not the US?

This is the question that causes the most confusion, because patients read "generic Ozempic launches" headlines and reasonably assume the US is next. It is not, and the reason is purely how patent law treats the same molecule in different countries.

In the US, Novo Nordisk received Patent Term Adjustment (compensating the company for delays at the US Patent Office) and Patent Term Extension (compensating for the years spent in FDA review), which together added roughly five years to the semaglutide compound patent — moving it from March 2026 to December 2031. India, by contrast, does not grant the same kinds of extensions. So in March 2026, when the base semaglutide patent lapsed in India, more than 40 Indian drugmakers launched generic versions at a small fraction of the US price — one firm reportedly pricing a starter dose near $14 per month. Brazil and China are on similar, earlier timelines.

The same molecule, two patent systems, two very different generic dates. Independent analyses of this gap estimate that the five extra years of US protection translate into roughly $166 billion in additional US revenue for Novo Nordisk — which is precisely why the extensions exist and precisely why US patients will wait until at least the 2031–2032 window.

What about biosimilars — are those coming sooner?

A reasonable follow-up question, because GLP-1 agonists are large peptide drugs and the word "biosimilar" gets used loosely. The short answer: semaglutide and tirzepatide are regulated as drugs under NDAs, not biologics under BLAs, so they are challenged by generic ANDAs, not biosimilars. (The FDA Purple Book, not the Orange Book, tracks biologics and biosimilars; the weight-loss GLP-1s live in the Orange Book.) There is no separate, faster "biosimilar" lane that will deliver a cheaper Wegovy before the ANDA/patent timeline above allows. Liraglutide — the older daily GLP-1 in Saxenda (weight loss) and Victoza (diabetes) — has now gone generic (Teva launched the first US generic liraglutide for obesity), but liraglutide was approved years earlier and its patents had already run their course. It is currently the only true generic GLP-1 available in the US, and it is generally considered less effective and less convenient than the weekly semaglutide and tirzepatide injections.

What are the practical options before 2031?

If the patent record says generics are years away, what can a patient actually do today to lower the cost of a GLP-1? Setting aside any specific medical advice — these are decisions for a prescriber — the landscape in 2026 looks like this:

1. Branded drug, with coverage or manufacturer savings. Novo Nordisk and Eli Lilly both offer savings cards and, for commercially insured patients, capped copay programs. Manufacturer list prices for Wegovy and Zepbound run near $1,000–$1,350 per month before any discount. Federal policy is pressing on this from two directions: under the Inflation Reduction Act, CMS selected semaglutide (Ozempic, Rybelsus, Wegovy) in its second Medicare negotiation cycle, with negotiated maximum fair prices taking effect January 1, 2027 — roughly $274 per month for Ozempic/Rybelsus and about $386 for Wegovy, a discount of roughly 71% off the 2024 list price — and a separate most-favored-nation agreement brought Medicare semaglutide to about $245 per month starting in 2026. These negotiated prices apply to defined Medicare populations, not the commercially insured or cash-pay market, and they are not generics — the patents stay in force.
2. The newly generic liraglutide. A true FDA-approved generic now exists for liraglutide, the older daily GLP-1. It is cheaper than branded Wegovy/Zepbound but also less effective for weight loss and requires daily rather than weekly injection.
3. Compounded GLP-1s. During the semaglutide and tirzepatide shortages, Section 503A and 503B compounding pharmacies filled a real access gap at a fraction of the brand price (often $200–$400/month). That window is closing as the FDA works through its 503B bulk-substances policy; compounded versions are not FDA-approved generics, carry sterility and dosing-error risks, and exist in a shifting legal zone. Our compounded GLP-1 safety and FDA timeline covers this in detail — including the serious adverse-event reports that have accompanied it.
4. Wait. For patients whose primary goal is long-term weight management and who can wait, the patent record is the only honest forecast: real generic semaglutide in the early 2030s, real generic tirzepatide in the late 2030s.

What does the slow generic timeline mean for aesthetic patients?

This is where the GLP-1 patent story connects to why an aesthetic-medicine reference covers it at all. The same wave of patients driving demand for facial-volume restoration and post-weight-loss body contouring is the wave whose access is gated by these prices. Three points matter for patients and providers planning around GLP-1-driven change:

• Cost constrains who stays on the drug. GLP-1s work only while taken; weight (and the facial fat pads that come with it) tends to return after discontinuation. A decade-long wait for affordable generics means the population sustaining stable, long-term weight loss — the ideal candidate for body contouring after GLP-1 weight loss — is smaller than the headline demand suggests, concentrated among the well-insured.
• Timing aesthetic work to a stable weight still matters. Because staying on the drug long-term is expensive and discontinuation often reverses weight loss, the right moment for post-weight-loss facial rejuvenation or treatment of Ozempic face is after a patient has reached a weight they can realistically maintain — which, given cost-driven stop-start patterns, is harder to identify than the marketing implies.
• Cheaper access will eventually widen the aesthetic pipeline. When generics finally arrive in the 2030s, the population achieving significant, sustained weight loss will expand, and with it the population seeking the sequelae — volume loss, skin laxity, contouring. Providers planning capacity for that demand should watch the 2031–2032 semaglutide window as the inflection point.

The key dates in one place

Because the GLP-1 patent story is scattered across patents, exclusivities, settlements, and policy actions, here is the consolidated timeline the rest of this page explains:

The gap between the compound-patent date and the "realistic earliest" date is the whole game. A compound patent expiring does not automatically yield a generic — it merely opens the door for a generic challenger to win (or settle) the remaining formulation and device patents in court. That is why semaglutide's 2031 compound date becomes a ~2032 market entry, and why tirzepatide's 2036 compound date becomes a plausibly 2039–2041 entry.

Why do patents get extended? PTA and PTE, explained

Two specific legal mechanisms are doing the work that keeps GLP-1s expensive for an extra five years in the US, and they are worth naming because they explain the India-versus-US gap directly:

• Patent Term Adjustment (PTA) compensates a patent owner when the US Patent and Trademark Office takes too long to process the application. Because the semaglutide patent sat in the USPTO for years beyond the standard, the clock was extended.
• Patent Term Extension (PTE) compensates a drug owner for the years a product spent in FDA clinical review before approval, during which the patent was running but the drug could not be sold.

Together, PTA and PTE pushed the semaglutide '343 patent from its nominal March 2026 expiry to December 2031. India and many other jurisdictions do not grant equivalent extensions, which is precisely why the same molecule went generic there in March 2026 while remaining patent-protected in the US for five more years. These extensions are legal, routinely granted, and routinely criticized by access advocates — but they are the mechanism, not a mistake in the data.

What about the oral GLP-1 pipeline — does that change the timeline?

A separate, faster-moving story is the next generation of GLP-1 drugs, which will compete with semaglutide and tirzepatide long before generics of the current drugs arrive. The most watched candidate is orforglipron, Eli Lilly's oral (pill) GLP-1 agonist, which has shown weight loss in late-stage trials reported as superior to oral semaglutide (Rybelsus). Danuglipron, another oral candidate, and Viking Therapeutics' oral entries are also in development. These are not generics of semaglutide or tirzepatide — they are new molecules with their own patent lives — so they will not make Wegovy or Zepbound cheaper. What they may do is give the market a non-injectable alternative within the branded-pricing window, which is a different kind of access improvement than a generic launch. For patients who specifically cannot or will not inject, the arrival of an effective oral GLP-1 around the late 2020s may matter more than the 2031 semaglutide patent cliff — but it is a branded-competition story, not a cheap-generic story.

How to read the Orange Book yourself

The point of sourcing these dates directly from the FDA Orange Book rather than a secondary tracker is that you can verify them yourself in a few minutes, and the record changes over time as companies list new patents. The workflow:

1. Go to the FDA Orange Book online (accessdata.fda.gov/scripts/cder/ob) and search by active ingredient — "semaglutide" or "tirzepatide."
2. The result lists every brand (Ozempic, Wegovy, Rybelsus for semaglutide; Mounjaro, Zepbound for tirzepatide) with its NDA number and whether it is the Reference Listed Drug.
3. For each product, the "Patent and Exclusivity" tab lists every patent with its number, expiry, and whether it covers the drug substance, the drug product, or a method of use — plus any exclusivity codes and their expiry.
4. The latest patent expiry across the formulation and method-of-use patents (not just the compound patent) is what determines the realistic ceiling on generic entry.

The Orange Book is a snapshot; companies add patents as they win them, so the "latest listed patent" date tends to creep outward. That is why independent analysts who re-landscape the filings periodically (I-MAK, Markman Advisors, GreyB) often report later realistic entry dates than the headline compound-patent date implies.

Frequently asked questions

Is there a generic Ozempic or Wegovy available in the US right now? No. The semaglutide compound patent runs until December 5, 2031, and generic entry is expected around 2032 at the earliest. Compounded semaglutide is not an FDA-approved generic.

Is there a generic Zepbound or Mounjaro? No. Tirzepatide's compound patent runs until January 5, 2036, and realistic generic entry is estimated at 2036–2041.

What is the difference between the Orange Book and the Purple Book? The Orange Book lists approved drugs (NDAs/ANDAs) and the patents and exclusivities that protect them — this is where semaglutide and tirzepatide live. The Purple Book lists licensed biological products and biosimilars (BLAs).

Why did India get generic semaglutide in 2026? India does not grant the same patent-term extensions the US does, so the base semaglutide patent expired there in March 2026, allowing immediate generic launch. The US extended the same patent to December 2031.

Is compounded semaglutide the same as generic semaglutide? No. Compounded semaglutide is pharmacy-compounded and not FDA-approved; it carries different safety and legal status than a generic that has passed FDA's ANDA review. See our compounded GLP-1 guide.

Will Medicare negotiation make Wegovy cheaper before 2031? Semaglutide was selected in Medicare's second drug-price-negotiation cycle, with negotiated maximum fair prices taking effect January 1, 2027 (roughly $274/month for Ozempic/Rybelsus and about $386/month for Wegovy), and a separate most-favored-nation deal brings Medicare semaglutide to about $245 starting in 2026. These are real price reductions for defined Medicare beneficiaries — they are not generics, the patents remain in force, and they do not directly help cash-pay or most commercially insured patients.

The bottom line

Read straight from the FDA Orange Book, the patent record gives an unambiguous forecast: US generic semaglutide is a roughly early-2030s event, US generic tirzepatide is a late-2030s event, and the only cheaper options before then are the newly generic liraglutide (less effective) and compounded GLP-1s (not FDA-approved, with a closing legal window and real safety caveats). For patients and providers in aesthetic medicine, that decade-long gap shapes who can realistically sustain the weight loss that drives facial-volume and body-contouring demand — and the 2031–2032 semaglutide window is the date to watch for when that demand finally broadens.

Sources

• U.S. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) — patents and exclusivity listings for semaglutide (Ozempic NDA 209637; Wegovy NDA 215256; Rybelsus NDA 213051) and tirzepatide (Mounjaro NDA 215866; Zepbound NDA 217806). https://www.accessdata.fda.gov/scripts/cder/ob/
• U.S. FDA. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
• I-MAK (Initiative for Medicines, Access & Knowledge). "The Heavy Price of GLP-1 Drugs" — patent landscaping of semaglutide and tirzepatide. https://www.i-mak.org/glp-1
• C&EN (American Chemical Society). "Looming GLP-1 drug patent expirations draw generics firms" (2025). https://cen.acs.org/pharmaceuticals/Looming-GLP-1-drug-patent/103/web/2025/12
• Fierce Pharma. "Generic versions of Novo's semaglutide launch today in India" (March 20, 2026). https://www.fiercepharma.com/
• Drugs.com. Generic Wegovy and Generic Mounjaro availability pages (updated 2026). https://www.drugs.com/availability/generic-wegovy.html
• KFF. "Key Facts About Medicare Drug Price Negotiation" (negotiated maximum fair prices for semaglutide effective January 1, 2027; MFN pricing context). https://www.kff.org/medicare/key-facts-about-medicare-drug-price-negotiation
• AMCP. "Federal Update: CMS Releases IPAY 2027 Negotiated Prices" — semaglutide maximum fair price ~$274 (Ozempic/Rybelsus) and ~$386 (Wegovy), effective January 1, 2027; Novo Nordisk MFN price of $245 starting in 2026. https://www.amcp.org/sites/default/files/2025-12/Federal%20Update_CMS%20Releases%20IPAY%202027%20Negotiated%20Prices.pdf
• Markman Advisors. Semaglutide patent landscape analysis. https://www.markmanadvisors.com/blog/2025/2/7/
• AestheticMedGuide. Compounded GLP-1 safety and FDA timeline. https://aestheticmedguide.com/blog/compounded-glp1-semaglutide-tirzepatide-fda-safety